The high frequency of mutations in cancer cells which result in altered cell cycle regulation and growth signal transduction, conferring a proliferative advantage, indicates that many of these aberrant mechanisms may be strategic targets for cancer therapy. The macrolide fungicide rapamycin, a natural product with potent antimicrobial, immunosuppressant, and anti-tumor properties, inhibits the translation of key mRNAs of proteins required for cell cycle progression from G 1 to S phase. Rapamycin binds intracellularly to the immunophilin FK506 binding protein 12 (FKBP12), and the resultant complex inhibits the protein kinase activity of a protein kinase termed mammalian target of rapamycin (mTOR). The inhibition of mTOR, in turn, blocks signals to two separate downstream pathways which control the translation of speci®c mRNAs required for cell cycle traverse from G 1 to S phase. Blocking mTOR aects the activity of the 40S ribosomal protein S6 kinase (p70 s6k ) and the function of the eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), leading to growth arrest in the the G 1 phase of the cell cycle. In addition to its actions on p70 s6k and 4E-BP1, rapamycin prevents cyclin-dependent kinase activation, inhibits retinoblastoma protein (pRb) phosphorylation, and accelerates the turnover of cyclin D1 that leads to a de®ciency of active cdk4/cyclin D1 complexes, all of which can inhibit cell cycle traverse at the G 1 /S phase transition. Both rapamycin and CCI-779, an ester analog of rapamycin with improved pharmaceutical properties and aqueous solubility, have demonstrated impressive activity against a broad range of human cancers growing in tissue culture and in human tumor xenograft models, which has supported the development of compounds targeting rapamycin-sensitive signal-transduction pathways. CCI-779 has completed several phase I clinical evaluations and is currently undergoing broad disease-directed ecacy studies. The agent appears to be well tolerated at doses that have resulted in impressive anti-tumor activity in several types of refractory neoplasms. Important challenges during clinical development include the de®nition of a recommended dose range associated with optimal biological activity and maximal therapeutic indices, as well as the ability to predict which tumors will be sensitive or resistant to CCI-779. Oncogene (2000) 19, 6680 ± 6686.
Keywords: rapamycin; CCI-779; signal transduction; clinical development Cell proliferation is a complex multifaceted process that requires the synthesis of essential regulatory proteins involved in the transduction of extracellular and autocrine proliferative stimuli. Since several of these highly regulated processes are aberrant in many types of cancers, conferring a proliferative advantage, they are potential strategic targets for therapeutic development against cancer (Sherr, 2000) . Indeed, several novel classes of therapeutics that interfere with discrete essential elements of aberrant signal transduction and cell cycle regulation, such as inhibitors of various receptor tyrosine kinases, oncogenes, critical proteins involved in signal transduction (e.g. Ras, Raf), and cyclin-dependent kinases, are being developed as anti-cancer agents (Rowinsky et al., 1999, Senderowicz and Sausville 2000) . One such agent, rapamycin (sirolimus; Rapamune 1 ; Wyeth-Ayerst, PA, USA), a macrolide fungicide isolated from the bacteria Streptomyces hygroscopicus, possesses potent antimicrobial, immunosuppressant, and antitumor properties (Baker et al., 1978; Sehgal et al., 1975; Vezina et al., 1975) . Because of its profound immunosuppressive actions, rapamycin was initially developed and received regulatory approval for the indication of prevention of allograft rejection following organ transplantation (Sehgal, 1995) . The antiproliferative actions of rapamycin have been demonstrated to be due to its ability to modulate critical signal transduction pathways that link mitogenic stimuli to the synthesis of proteins required for cell cycle traverse from G 1 to S . Impressive antiproliferative activity has been demonstrated following treatment of a diverse types of experimental tumors with rapamycin (Eng et al., 1984 , Muthukkumar et al., 1995 Seuerlein and Rozengurt, 1996) . However, the poor aqueous solubility and chemical stability of rapamycin precluded its clinical development as an anti-cancer agent. Recently, a series of rapamycin analogs with improved aqueous solubility and stability have been synthesized and evaluated. CCI-779 (Wyeth Ayerst, PA, USA), a soluble ester analog of rapamycin, was selected for development as an anti-cancer agent based on its prominent anti-tumor pro®le and favorable pharmaceutical and toxicological characteristics in preclinical studies (Gibbons et al., 2000) . Several phase I studies of CCI-779 have been completed and diseasedirected ecacy evaluations in a number of tumor types are being performed (Raymond et al., 2000; Hidalgo et al., 2000) . This review will summarize the principal mechanisms of anti-tumor action of rapamycin, speci®cally its eect on rapamycin-sensitive signal transduction pathways, and will discuss the preliminary results of experimental and clinical studies with this novel class of anti-cancer agents. 
Mechanism of action of rapamcyin and rapamycin analogs
Rapamycin, and its ester analog, CCI-779, uniquely interfere with cell cycle progression from G 1 to S phase in response to proliferative stimuli by blocking the translation of mRNAs of essential cell cycle proteins . The principal mechanisms responsible for these actions, which have been elucidated only over the last several years, are graphically depicted in Figures 1 and 2 .
Upstream actions and the target of rapamycin
Rapamycin binds intracellularly to members of the immunophilin family of FK506 binding proteins (FKBPs), inhibiting their enzymatic activity as prolyl isomerases (Heitman et al., 1991; Koltin et al., 1991; Fruman et al., 1995) . Although there are many members of the FKBP family, a large body of biochemical and genetic studies suggest that FKBP12 is the most important binding protein with respect to the rapamycin-sensitive signal transduction pathway (Heitman et al., 1991; Koltin et al., 1991; Fruman et al., 1995) . The resultant rapamycin-FKBP12 complex interacts with and inhibits the activity of a 290 kd kinase, termed mammalian target of rapamycin (mTOR) (also known as FRAP, RAFT1, and RAP1) (Figure 1 ) (Sabatini et al., 1994; Sabers et al., 1995; Brown et al., 1994; Chiu et al., 1994) . mTOR is a member of a recently identi®ed family of protein kinases termed phosphoinositide 3-kinase related kinases (PIKKs), which are involved in many critical regulatory cellular functions pertaining to cell cycle progression, cell cycle checkpoints that govern cellular responses to DNA damage, DNA repair, and DNA recombination (Sarkaria et al., 1998) .
In response to growth stimuli, quiescent cells increase the translation of a subset of mRNAs whose protein products are required for traverse through the G 1 phase of the cell cycle. mTOR regulates essential signal transduction pathways and is involved in the coupling of growth stimuli with cell cycle progression. Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) (PI3K/Akt) appears to be the key modulatory factor in the upstream pathway by which growth factor-growth factor receptor interactions aect the phosphorylation state of mTOR (Figure 1) (Downward 1998; Scott et al., 1998; Nave et al., 1999) . PI3K plays a central role in cellular proliferation, motility, neovascularization, viability, and senescence and is upregulated in cancer cells (Shayestech et al., 1999; Cantley et al., 1991) . Its main physiological function is the phosphorylation of the D3 portion of membrane phosphoinositols (Cantley et al., 1991; Carpenter et al., 1990) . Although the role of PI3K and its lipid products in signal transduction processes is not clear, the activity of this enzyme on tyrosine kinases induces mitogenesis, cellular growth, and cellular transformation (Carpenter et al., 1990; Varticovski et al., 1994; Hu et al., 1995) . Recently, several studies have investigated the role of small molecule-inhibitors of PI3K as potential tumor suppressor agents. For example, the¯avonoid derivative, LY294002 (Eli Lilly, Indianapolis, IN, USA), a potent PI3K inhibitor, is a competitive, reversible inhibitor of the ATP binding site of the enzyme (Vlahos et al., 1994; Hu et al., 2000) . The agent induces G 1 arrest in proliferating cells, leading to almost complete inhibition of melanoma cell proliferation, partial inhibition of MG-63 osteosarcoma cell growth, and inhibitor of OVCAR-3 ovarian carcinoma inducing prominent apoptotic eects (Hu et al., 2000; Casagrande et al., 1998; Thomas et al., 1997) . The inhibitor also completely inhibits the retinoblastoma protein (pRb) hyperphosphorylation that normally occurs during G1 progression and induces up-regulation of the cyclin-dependent kinase inhibitor p27 (Casagrande et al., 1998) .
There are ample experimental data indicating that mTOR functions downstream of the PI3K/Akt pathway and is phosphorylated in responses to stimuli that activate the PI3K/Akt pathway (Scott et al., 1998; Nave et al., 1999; Hu et al., 1995; Sekulic et al., 2000) . PI3K and Akt are considered proto-oncogenes, and the pathway is inhibited by the tumor suppressor gene PTEN (Wu et al., 1998) . There are other signaling pathways that are activated downstream of PI3K, but the Akt pathway is of particular interest because of its role in inhibiting apoptosis and promoting cell proliferation by aecting the phosphorylation status of cell-survival and apopotosis-inducing proteins like BAD (Downward, 1998) .
Downstream effects
Following activation via phosphorylation, mTOR modulates two separate downstream pathways that control translation of speci®c subsets of mRNAs including the eukaryotic initiation factor 4E binding protein-1 (4E-BP1), also known as PHAS-1 (phosphorylated heat-and acid-stable protein), and the 40S ribosomal protein S6 kinase (p70 s6k ) (Figure 1 ) (Brunn et al., 1997; Gingras et al., 1998; Hara et al., 1997) . There is ample evidence indicating that the activation of either PI3K or Akt is sucient to induce the phosphorylation of both 4E-BP1/PHAS-1 and p70 s6k through mTOR (Chung et al., 1994; Petrisch et al., 1995) . Furthermore, treatment of activated PI3K-or Akt-expressing cells with rapamycin blocks the phosphorylation of p70 s6k and 4E-BP1/PHAS-1, suggesting that mTROR is required for these activities Burgering and Coer, 1995) .
The ®rst downstream regulator modulated by the phosphorylation status of mTOR, 4E-BP1/PHAS-1, is a low molecular-weight protein that inhibits the initiation of translation through its association with eIF-4E, the mRNA cap-binding subunit of the eukaryotic initiation factor-4 (eIF-4F) complex ( Figure  2 ). The binding of 4E-BPs to eIF-4E is dependent on the phosphorylation status of 4E-BP. In the unphosphorylated state that predominates in quiescent cells, 4E-BP1/PHAS-1 binds to eIF-4E which inhibits its activity . In response to proliferative stimuli, 4E-BP1/PHAS-1 becomes phosphorylated through the action of mTOR and other kinases which decrease its binding anity for eIF-4E. These actions promote the dissociation of the 4E-BP1/ PHAS-1 complex, increasing the availability of eIF-4E, which can then bind to eIF-4G, -4B, and -4A, forming the multisubunit eIF-4F complex. These interactions lead to an increase in the translation of mRNAs with regulatory elements in the 5'-untranslated region such as cyclin D1 and ornithine decarboxylase Rosenwald et al., 1995; Shantz and Pegg 1995) . In contrast, growth factor deprivation or treatment with rapamycin results in the dephosphorylation of 4E-BP1/PHAS-1, an increase in eIF-4E binding, and a concomitant decrease in the translation of mRNAs for cell cycle progression from G 1 to S phase, as shown in Figure 2 (Brunn et al., 1997; Gingras et al., 1998) .
The second downstream target modulated by mTOR is the kinase p70 s6k . Upon activation by proliferative stimuli mediated by the PI3K/Akt signal transduction pathway, mTOR phosphorylates/activates p70 s6k , which, in turn, phosphorylates the 40S ribosomal protein S6 (Hu et al., 2000) . The phosphorylation of S6 leads to the recruitment of the 40S ribosomal subunit into actively translating polysomes, thereby enhancing the translation of mRNAs with a 5' terminal oligopolypyrimidine including those that encode for ribosomal proteins, elongation factors, and insulin growth factor ± II. Rapamycin treatment results in a rapid and profound dephosphorylation of p70 s6k , suppressing its activity (Seuerlein and Rozengurt 1996; Grewe et al., 1999) .
In addition to its well characterized inhibitory actions on p70 s6k and 4E-BP1/PHAS-1, rapamycin interferes with other intracellular processes involved in cell cycle progression which undoubtedly contribute to its antiproliferative actions. These other actions are particularly important in exponentially growing cells were inhibition of p70 s6k phosphorylation by rapamycin does not result in G1 cell cycle arrest (Kawamata et al., 1998) . Rapamycin increases the turnover of cyclin D1 at the mRNA and protein level (Hashemolhosseini et al., 1998) . This eect, in addition to the decrease translation of cyclin D1 mRNA subsequently to 4E-BP1/PHAS inhibition, results in a relative de®ciency of cyclin D1 in the cdk4/cyclin D1 complexes required for retinoblastoma protein phosphorylation (Morice et al., 1993; Nourse et al., 1994) . Rapamycin also blocks the elimination of the cyclin dependent kinase (cdks) inhibitor p27 and facilitates the formation of the cyclin/cdks-p27 complexes (Nourse et al., 1994; Luo et al., 1996) . Furthermore, in exponentially growing cells, rapamycin upregulates p27 at both the mRNA and protein level and inhibits cyclin-A-dependent kinase activity (Kawamata et al., 1998 ). It appears that, although rapamycin treatment results in cell cycle arrest at the G1/S transistion, the precise mechanism responsible for this eect is both cell cycle-and cell type-speci®c.
By inhibiting the translation of critical mRNAs involved in the G 1 to S phase transition in response to mitogenic stimuli, and by interfering with the balance of cyclin/cyclin-dependent-kinase/cyclin-dependent kinase inhibitors in the early phases of the cell cycle, rapamycin inhibits the growth of cancer cells. Rapamycin exerts concentration-dependent inhibition of cell proliferation and tumor growth in a variety of murine and human cancers growing in both cell culture and xenograft models including B16 melanoma, P388 leukemia, MiaPaCa-2 and Panc-1 human pancreatic carcinoma and tumors derived from B-cell lymphoma, small cell lung cancer carcinoma, and childhood rhapdomyosarcoma (Muthukkumar et al., 1995; Seufferlein and Rozengurt 1996; Hosoi et al., 1999) . Rapamycin also induces p53-independent apoptosis in childhood rhabdomyosarcoma cell lines and enhances the apoptotic-inducing eects of cisplatin in murine Tcell, human HL-60 promyelocytic leukemia, and human ovarian SKOV3 cancer cell lines (Hosoi et al., 1999; Shi et al., 1995) .
Clinical development
The unfavorable pharmaceutical properties of rapamycin, particularly its poor aqueous solubility and instability, preclude its clinical development as an anti-cancer agent, and, therefore, soluble ester analogs were synthesized and evaluated as a collaborative eort between investigators at Wyeth-Ayerst and the National Cancer Institute. CCI-779, a water soluble ester analog of rapamcyin, was selected for further development based on favorable pharmaceutical, toxicologic, and antitumor pro®les in preclinical evaluations. In the National Cancer Institute human tumor cell line screen, CCI-779 and rapamycin demonstrated similar anti-tumor pro®les and potencies (Pearson correlation coecient, 0.86), with IC 50 values frequently less than Targeting rapamycin-sensitive pathway M Hidalgo and EK Rowinsky 10 78 M (Gibbons et al., 2000) . Platelet-derived growth factor stimulation of the human glioblastoma line T98G was markedly inhibited (IC 50 , 1 pM), consistent with its proposed mechanism of action as an inhibitor of signal transduction, and growth-inhibited cells were arrested in G 1 (Gibbons et al., 2000) . In studies involving cancer cell lines growing in tissue culture, human prostate, breast, and small cell lung carcinomas, glioblastoma, melanoma, and T-cell leukemia were among the most sensitive cancers to CCI-779, with IC 50 values in the nanomolar range (Gibbons et al., 2000) . Signi®cant growth inhibition was also observed following treatment of a variety of human tumor xenografts with CCI-779, but the preponderance of tumor growth inhibition, in contrast to overt tumor regression, suggests that subsequent disease-directed trials should be designed to assess this potential outcome. In addition, several intermittent CCI-779 dosing regimens were eective in human tumor xenograft studies, which is important in view of the possibility that prolonged immunosuppression can result from both rapamycin and CCI-779 administered on continuous dose-schedules and since the immunosuppressive eects of rapamycin analogs have been demonstrated to resolve in approximately 24 h following treatment (Gibbons et al., 2000) .
Thus far, CCI-779 has been evaluated in two phase I studies, in which the agent has been administered as a 30-min IV infusion weekly and as a 30-min IV infusion daily for 5 days every 2 weeks (Raymond et al., 2000; Hidalgo et al., 2000) . These schedules were selected for initial clinical evaluation to avoid prolonged druginduced immunosuppression which resolves shortly after drug treatment. However, similar to the traditional paradigm used to develop nonspeci®c cytotoxic agents, these phase I studies were designed to determine the maximum tolerated dose based on dose-limiting toxicities as classically de®ned. To date, 16 patients have been treated with CI-779 at doses ranging from 7.5 to 220 mg/m 2 /week on the weekly schedule and 35 patients have received doses ranging from 0.75 to 24 mg/m 2 /day on the daily for-5-days every-2-week schedule. The principal toxicities of CCI-779 have included dermatologic toxicity, myelosuppression, reversible elevations in liver function tests, and asymptomatic hypocalcemia. The cutaneous eects, which have been relatively more common with CCI-779 on the weekly schedule, have been multifaceted. Dermatologic manifestations have included aseptic folliculitis, erythematous maculopapular rashes, ezcematoid reactions, dry skin, vesicular lesions, and nail disorders. The principal hematologic toxicity has been thrombocytopenia, whereas anemia, leukopenia, and neutropenia have generally been less common and severe. Other toxicities and biochemical abnormalities, which have generally been mild to moderate in severity, reversible, and noted over wide dosing ranges include mucositis, hypertriglyceridemia, hypercholesterolemia, and reversible decrements in serum testosterone. The maximum tolerated doses of CCI-779 on the daily-for-5-day-every-2-week schedule are projected to be 15 and 24 mg/m 2 /day in patients with minimal or extensive prior myelotoxic therapy, respectively, whereas the maximum tolerated dose has not been determined for CCI-779 administered on a weekly schedule. The preliminary results of pharmacokinetic studies indicate dose-dependent pharmacokinetics, elimination half-life values of approximately 15 ± 17 h, and preferential partitioning of CCI-779 in red blood cells (Raymond et al., 2000; Hidalgo et al., 2000) . Major tumor responses (partial responses; 450% reduction in the sum of the bidimensional product of all measurable lesions) have been noted in previously-treated patients with renal cell carcinoma and non-small cell lung carcinoma, and minor tumor responses (550% reduction in the sum of the bidimensional product of all measurable lesions) have been observed in previously-treated patients with soft tissue sarcoma, serous papillary carcinoma of the endometrium, breast carcinoma, squamous cell carcinoma of the skin, and non-Hodgkins lymphoma. The fact that CCI-779 consistently induced tumor regressions at relatively nontoxic doses in the phase I studies is particularly noteworthy, since this observation suggests that the optimal therapeutic dose of CCI-779 may be lower than the maximum tolerated dose.
Disease-directed ecacy studies of CCI-779 in a broad range of tumor types will be initiated following the completion of phase I studies. Based on the results of experimental studies involving malignant gliomas that rely on paracrine or autocrine stimulation of receptors that trigger the PI3/Akt pathway, studies directed at assessing the anti-tumor activity of CCI-779 in patients with glioma are planned. However, since CCI-779 is principally metabolized by cytochrome P450 mixed function oxidases that are induced by many types of anticonvulsant agents commonly coadministered to patients with malignant gliomas, the toxicities, pharmacokinetics, and optimal dose-schedule of CCI-779 are being evaluated in patients concurrently receiving treatment with P450 mixed function oxidaseinducing anticonvulsant agents. In addition, phase I studies evaluating the feasibility of administering CCI-779 in combination with various cytotoxic chemotherapeutics such as 5-¯uorouracil and gemcitabine are underway. An oral formulation of CCI-779, which would increase the feasibility of protracted drug administration, is also in early clinical development.
For CCI-779 and other rationally developed agents, in which tumor growth inhibition and delay are predominant therapeutic eects in preclinical studies, traditional phase II tumor screening paradigms that focus solely on tumor regression may be suboptimal since clinically signi®cant inhibitory eects on tumor growth may not be detected (Gelmon et al., 1999) . Although regressions of well established tumors have been noted in preclinical studies of CCI-779, tumor growth delay is the principal therapeutic eect of the agent. In addition to the traditional screening endpoint, tumor regression, disease-speci®c screening studies or phase II clinical trials, at which time`go or no go' decisions are made about the subsequent development of CCI-779 and other antirproliferative agents, must be designed to evaluate inhibition of tumor growth. Possible clinical endpoints that have been proposed for the evaluation of antiproliferative agents include time to progression, the proportion of patients without progressive disease as their best response, symptomatic bene®t, and reduction in tumor markers. Potential surrogate endpoints include inhibition at the target, particularly if this eect can be validated to re¯ect tumor growth delay and/or regression in preclinical models, and assessments of cell proliferation by functional imaging (e.g. positron emission tomography, nuclear magnetic resonance scanning). However, randomized clinical trials are the optimal means to evaluate any agent's eect on tumor growth and/or related surrogate endpoints Nevertheless, tumor regression has been observed with CCI-779 and other signal transduction inhibitors in both preclinical studies and phase I clinical trials, which may occur when the inhibition of tumor growth is of sucient magnitude so that tumor cell death, possibly through apoptosis, exceeds the rate of tumor cell proliferation Ferry et al., 2000) . Therefore, the traditional endpoint of tumor regression, which is used to screen for the activity of nonspeci®c cytotoxic agents, may be an appropriate endpoint in nonrandomized phase II studies of antiproliferative agents that have the potential for inducing tumor regression as discerned from preclinical studies.
Another important issue pertaining to the development of CCI-779 and other rationally designed inhibitors of signal transduction is the need to assess relevant target eects in order to guide dose selection and facilitate the assessment of bene®t in clinical trials. The selection of an appropriate dose for broad diseasedirected trials of CCI-779 is especially challenging since objective anti-tumor activity has been observed in patients treated with a wide range of doses. Unlike the situation with nonspeci®c cytotoxic agents, in which the relationship between dose and response is roughly linear and the maximum tolerated dose is sought, preclinical data suggest that therapeutic activity generally plateaus above a`threshold' dose. In contrast, since the relationship between dose and toxicity is still likely to be linear, the selection of an optimal biological dose for clinical trials is desirable. However, eorts to precisely assess target eects during clinical investigations are extremely complex, requiring an understanding of the agent's precise mechanism of activity, and the availability of assays that measure relevant drug eects at the tumor target or in surrogate tissues that re¯ect inhibition at the target. Still, the availability of feasible biological assays capable of assessing inhibition at the target does not ensure that such eects will relate to clinical bene®t. Since the intracellular target of CCI-779 and its downstream signaling pathways have been well characterized, the development of assays that measure the phosphorylation status of either 4E-BP1/PHAS and/or p70 s6k , enabling evaluation of whether patients are receiving pharmacodynamically-active doses, is feasible (Yatsco and Aspeslet, 1998). Nevertheless, a critical issue is whether these downstream eects correlate with the anti-tumor activity of CCI-779, particularly since malignant cells can traverse the cell cycle and proliferate despite the dephosphorylation of 4E-BP1/ PHAS and the inactivation of p70 s6k by rapamycin (Kawamata et al., 1998; Yatsco and Aspeslet, 1998) . These observations suggest that either these pathways are not the only mechanisms by which cell cycle progression is regulated, or that mTOR-4E-BP1/ PHAS-1 and mTOR-p70 s6k pathways are redundant. Although assessing drug eects with such assays may facilitate the determination of whether a delivered dose is pharmacologically-active, the assay may not necessarily predict drug ecacy since the assays may be assessing targets that are not related to the eects of the agent on proliferation. Alternatively, downstream factors may render the tumor cells resistant. Therefore, optimal assessments of target inhibition in tumor or surrogate tissues may require additional information about the relevance of target inhibition in terms of cell proliferation, cell cycle arrest, apoptosis, and/or angiogenesis. Such assays will ultimately be validated following the acquisition of late-stage clinical outcome data, particularly information pertaining to tumor regression, time to progression, clinical bene®t, and survival, in large numbers of patients. At this juncture, the utility and feasibility of assays measuring the inactivation of p70 s6k in peripheral blood mononuclear cells are being assessed in the course of early diseasedirected ecacy studies of rapamycin.
Another important issue regarding the optimal development of CCI-779 is whether tumors with speci®c molecular abnormalities are particularly sensitive or resistant to the antiproliferative eects of CCI-779. Tumors that rely on paracrine or autocrine stimulation of receptors that constitutively stimulate the PI3/Akt/mTOR pathway or tumors with mutations that activate the PI3K/Akt signal transduction pathway may depend on rapamycin-sensitive pathways for growth and thus may be especially sensitive to rapamycin analogs. For example, mutations of the PTEN tumor suppresor gene which encode a lipid phosphatase that inhibits PI3K-dependent activation of PKB/Akt, occur commonly in a wide variety of tumor types (Hosoi et al., 1998; Besson et al., 1999; Teng et al., 1997) . The PI3K/Akt pathway is constitutively activated in tumors with PTEN mutations and these neoplasms are generally resistant to apoptosis. As predicted, the preliminary results of experimental studies in our laboratory indicate that breast cancer cell lines with PTEN mutations are extraordinarily sensitive to rapamycin (Hidalgo M, personal communication) . In addition to increased sensitivity to rapamycin conferred by mutations of the PTEN suppressor oncogene, abnormalities of regulators of the G 1 checkpoint such as pRB, p16, p27, and cyclin D1 may also increase the sensitivity of tumors to rapamycin and may predict for drug ecacy (Sausville et al., 1999) . It is clear that de®ning the molecular characteristics of tumors of patients enrolled in clinical trials of CCI-779 may help to identify which patients may bene®t from treatment.
Conclusion
The natural product rapamycin, and its water-soluble ester analog, CCI-779, have potent immunosuppressant and antiproliferative properties stemming from their ability to modulate signal transduction pathways linking growth stimuli to the synthesis of speci®c proteins required for cell cycle progression from G 1 to S phase. Both rapamycin and CCI-779 profoundly inhibit the proliferation of a broad range of human tumors both in vitro and in vivo, which have supported the clinical development of this class of compounds. At this juncture, CCI-779, which possesses more favorable pharmaceutical properties than rapamcyin, is completing several phase I evaluations and is broad disease-directed ecacy studies are planned. CCI-779 is well tolerated at doses that have resulted in impressive antitumor activity against several types of refractory malignancies However, developmental challenges include the de®nition of recommended doses range for clinical use, the optimal disease-directed clinical trial paradigm enabling the appreciation of optimal biological activity and maximal therapeutic indices, as well as the ability to predict which tumors will be particularly sensitive to CCI-779.
